{
  "id": "clinical#general_68d35df8",
  "content": "Additional features:\n• The severity and duration of volatile inhalant withdrawal is related to the type of\ninhalant used and to the amount, frequency and duration of use of the specific\ninhalant.\n• Volatile inhalant withdrawal may be accompanied by persisting features\nof volatile inhalant intoxication or its medical complications, such as\nencephalopathy – especially when the inhalant used is lead-containing petrol/gasoline.\nMDMA or related Presenting features of MDMA or related drug withdrawal may include fatigue, lethargy,\ndrugs, including MDA hypersomnia or insomnia, depressed mood, anxiety, irritability, craving, difficulty in\nconcentrating and appetite disturbance.\nAdditional features\n• The above information primarily concerns withdrawal from MDMA. There is\ninsufficient information on the features and course of the withdrawal state from\ndrugs related to MDMA, including MDA, to fully characterize the associated\nwithdrawal states.\n• MDMA withdrawal is uncommon, reflecting the comparative rarity of MDMA\ndependence.\n• Onset of MDMA withdrawal typically occurs within 12–24 hours after last use,\nas blood concentrations decline. The features vary in type, severity, onset and\nduration according to the amount, frequency and duration of MDMA use prior to\ncessation of use.\n• The duration of MDMA withdrawal may be up to 10 days. Craving for MDMA may be",
  "metadata": {
    "source": "WHO ICD-11",
    "url": "https://icd.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "sleep"
    ],
    "is_clinical": false,
    "is_advice": false
  },
  "index_text": "General — General Additional features:\n• The severity and duration of volatile inhalant withdrawal is related to the type of\ninhalant used and to the amount, frequency and duration of use of the specific\ninhalant.\n• Volatile inhalant withdrawal may be accompanied by persisting features\nof volatile inhalant intoxication or its medical complications, such as\nencephalopathy – especially when the inhalant used is lead-containing petrol/gasoline.\nMDMA or related Presenting features of MDMA or related drug withdrawal may include fatigue, lethargy,\ndrugs, including MDA hypersomnia or insomnia, depressed mood, anxiety, irritability, craving, difficulty in\nconcentrating and appetite disturbance.\nAdditional features\n• The above information primarily concerns withdrawal from MDMA. There is\ninsufficient information on the features and course of the withdrawal state from\ndrugs related to MDMA, including MDA, to fully characterize the associated\nwithdrawal states.\n• MDMA withdrawal is uncommon, reflecting the comparative rarity of MDMA\ndependence.\n• Onset of MDMA withdrawal typically occurs within 12–24 hours after last use,\nas blood concentrations decline. The features vary in type, severity, onset and\nduration according to the amount, frequency and duration of MDMA use prior to\ncessation of use.\n• The duration of MDMA withdrawal may be up to 10 days. Craving for MDMA may be Additional features:\n• the severity and duration of volatile inhalant withdrawal is related to the type of\ninhalant used and to the amount, frequency and duration of use of the specific\ninhalant. • volatile inhalant with..."
}